Adding Ibrutinib to RICE or RVICI Provides No Benefit in Pediatric Rel/Ref B-NHL
Researchers sought to determine whether adding ibrutinib to multiagent chemotherapy would improve survival in pediatric patients with B-NHL.
Diagnosis & Disease Information
Recombinant Erwinia Asparaginase Is Efficacious in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Researchers sought to determine whether JZP458 could maintain adequate nadir serum asparaginase activity in patients with ALL/LBL.
Adding Bortezomib to DRC Does Not Improve PFS in Waldenström Macroglobulinemia
Researchers sought to determine whether adding bortezomib to DRC would improve survival in patients with Waldenström macroglobulinemia.
Long-Term Follow-Up Confirms Efficacy of N-AVD in Hodgkin Lymphoma
Researchers sought to determine whether N-AVD would continue to show a high response rate in patients with early-stage, unfavorable Hodgkin lymphoma.
New Model Using Ferroptosis-Related Genes Predicts Survival in Diffuse Large B-Cell Lymphoma
Researchers sought to determine the prognostic value of genes related to ferroptosis in DLBCL.
Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCL
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
R-MIV Is an Effective Induction Regimen for Patients With Primary Central Nervous System Lymphoma
Researchers sought to determine whether induction with R-MIV would be an effective treatment for primary CNS lymphoma.
Chronotherapy Study Shows Afternoon Regimens Better for Female Patients With DLBCL
A study evaluating the use of chronotherapy for hematologic cancers identifies how the approach can improve outcomes for some patients.
BV-AVD May Improve PET Results Among Some Patients with Hodgkin Lymphoma
Researchers sought to determine whether first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine would yield favorable results in HL.
“Severe4” Predicts Outcomes of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
- Loading...
Loading...
Loading... 
Loading...